Javascript must be enabled to continue!
Chronic Eosinophilic Leukemia with FIP1L1-PDGFRA Transcripts after Occupational and Therapeutic Exposure to Radiation
View through CrossRef
We present for the first time a 40-year-old male patient with a 20 year history of occupational exposure to radiation as a nuclear power plant worker, who developed FIP1L1-PDGFRA-positive chronic eosinophilic leukaemia 27 months after radiotherapy for testicular seminoma. After an one-year history of dry cough, itching and night sweats, the patient presented with an elevated leukocyte count with absolute eosinophilia of 14.2 × 109/L, bone marrow and lymph node involvement. Treatment with Imatinib was initiated, resulting in complete haematological remission at the sixth month and complete molecular response by nested primers reverse transcription polymerase chain reaction–at the end of the first year. This case contributes for the clinical heterogeneity of FIP1L1-PDGFA–positive myeloproliferative neoplasms and the possible role of occupational and therapeutic radiation, raising the question if one or both of them might be the causative factor.
Title: Chronic Eosinophilic Leukemia with FIP1L1-PDGFRA Transcripts after Occupational and Therapeutic Exposure to Radiation
Description:
We present for the first time a 40-year-old male patient with a 20 year history of occupational exposure to radiation as a nuclear power plant worker, who developed FIP1L1-PDGFRA-positive chronic eosinophilic leukaemia 27 months after radiotherapy for testicular seminoma.
After an one-year history of dry cough, itching and night sweats, the patient presented with an elevated leukocyte count with absolute eosinophilia of 14.
2 × 109/L, bone marrow and lymph node involvement.
Treatment with Imatinib was initiated, resulting in complete haematological remission at the sixth month and complete molecular response by nested primers reverse transcription polymerase chain reaction–at the end of the first year.
This case contributes for the clinical heterogeneity of FIP1L1-PDGFA–positive myeloproliferative neoplasms and the possible role of occupational and therapeutic radiation, raising the question if one or both of them might be the causative factor.
Related Results
Association between Polymorphic Variation at the IL5RA Locus and the Severity of FIP1L1-PDGFRA Positive Chronic Eosinophilic Leukaemia
Association between Polymorphic Variation at the IL5RA Locus and the Severity of FIP1L1-PDGFRA Positive Chronic Eosinophilic Leukaemia
Abstract
FIP1L1-PDGFRA is a cytogenetically cryptic fusion gene seen in a minority of patients with chronic eosinophilic leukaemia (CEL). Observations in mice have s...
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Abstract
A cervical rib (CR), also known as a supernumerary or extra rib, is an additional rib that forms above the first rib, resulting from the overgrowth of the transverse proce...
Case Report: Pediatric myeloid/lymphoid neoplasm with eosinophilia and PDGFRA rearrangement: The first case presenting as B-lymphoblastic lymphoma
Case Report: Pediatric myeloid/lymphoid neoplasm with eosinophilia and PDGFRA rearrangement: The first case presenting as B-lymphoblastic lymphoma
According to the latest WHO classification of hematopoietic malignancies, myeloid and lymphoid neoplasms with eosinophilia and gene rearrangements include three specific rare disea...
Local increase in IgE and class switch recombination to IgE in nasal polyps in chronic rhinosinusitis
Local increase in IgE and class switch recombination to IgE in nasal polyps in chronic rhinosinusitis
SummaryBackgroundChronic rhinosinusitis with nasal polyps is generally characterized by local Th2 inflammation and is categorized into two subtypes in Japan: eosinophilic chronic r...
Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing
Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing
Abstract
Although imatinib is clearly the treatment of choice for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia (CEL), little is known about optimal dosing, d...
Biomarker profiles and immune cell populations in distinct asthma endotypes
Biomarker profiles and immune cell populations in distinct asthma endotypes
<p dir="ltr">Asthma affects 260 million individuals globally and imposes a substantial health burden. Its hallmarks include chronic airway inflammation, airway hyperresponsiv...
Biomarker profiles and immune cell populations in distinct asthma endotypes
Biomarker profiles and immune cell populations in distinct asthma endotypes
<p dir="ltr">Asthma affects 260 million individuals globally and imposes a substantial health burden. Its hallmarks include chronic airway inflammation, airway hyperresponsiv...
Myosin-IIa Is Required for Leukemia Cell Extravasation and Its Inhibition Reduces Leukemia Dissemination and Prolongs Survival in a Mouse Model of Acute Lymphoblastic Leukemia
Myosin-IIa Is Required for Leukemia Cell Extravasation and Its Inhibition Reduces Leukemia Dissemination and Prolongs Survival in a Mouse Model of Acute Lymphoblastic Leukemia
Abstract
Background: Leukemia affects approximately 45,000 people each year in the USA with more than 20,000 fatalities. Many leukemia patients experience initial re...

